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Background:  Patients who sustain traumatic brain injury (TBI) and concomitant hemorrhagic 
shock (HS) are at high risk of high-magnitude inflammation which can lead to poor outcomes 
and death.  Blood purification by hemoadsorption (HA) offers an alternative intervention to 
reduce inflammation after injury.  We tested the hypothesis that HA would reduce mortality in a 
rat model of TBI and HS. 
Methods: Male Sprague Dawley rats were subjected to a combined injury of a controlled 
cortical impact (CCI) to their brain and pressure-controlled hemorrhagic shock (HS).  Animals 
were subsequently instrumented with an extracorporeal blood circuit that passed through a 
cartridge for sham or experimental treatment.  In experimental animals, the treatment cartridge 
was filled with proprietary beads (Cytosorbents;  Monmouth Junction, NJ) that removed 
circulating molecules between 5 KDa and 60 KDa.  Sham rats had equivalent circulation but no 
blood purification.  Serial blood samples were analyzed with multiplex technology to quantify 
changes in a trauma-relevant panel of immunologic mediators.  The primary outcome was 
survival to 96hr post-injury.   
Results:  HA improved survival from 47% in sham treated rats to 86% in HA treated rats.  There 
were no treatment-related changes in histologic appearance.  HA affected biomarker 
concentrations both during the treatment and over the ensuing four days after injury.  Distinct 
changes in biomarker concentrations were also measured in survivor and non-survivor rats from 
the entire cohort of rats indicating biomarker patterns associated with survival and death after 
injury.   
Conclusions:  Blood purification by non-selective HA is an effective intervention to prevent 
death in a combined TBI/HS rat model.  HA changed circulating concentrations of multiple 
inmmunologically active mediators during the treatment time frame and after treatment.  HA has 
been safely implemented in human patients with sepsis and may be a treatment option after 
injury. 
Keywords:  hemoadsorption; traumatic brain injury; hemorrhagic shock; cytokines; polytrauma 
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Background 
     Patients sustaining traumatic brain injuries (TBI) are often multiply injured and frequently 
present with concomitant hemorrhagic shock (HS) 
1,2
.  In patients with HS, TBI increases the
risk to develop high-magnitude sustained systemic inflammation, immunologic dysfunction, and 
multiple organ dysfunction syndrome (MODS) 
3-6
.  Conversely, the immunologic response and
excessive inflammation resulting from HS exacerbate the severity of TBI 
7,8
.  Under physiologic
conditions, the brain is largely isolated from systemic immune surveillance and inflammation by 
the blood brain barrier (BBB).  TBI disrupts this protective mechanism and systemic 
inflammation and the peripheral immune response to injury gain access to the brain while 
intracranial inflammation gains access to the systemic circulation
6,9-11
.  The reciprocating effects
of intracranial and systemic inflammatory responses propagate secondary injury to the brain 
8,12-
16
and peripheral organ dysfunction 
6,11
.
     Extensive research in animal models has demonstrated that pharmaceutical mitigation of 
intracranial inflammation improves histological scores and functional outcomes after TBI 
17
.
Accordingly, clinicians have attempted to improve outcomes after TBI by blocking inflammation 
to reduce secondary brain injury 
18-24
.  Unfortunately, unlike animal models, clinical 
interventions designed to mitigate inflammation have uniformly failed to improve neurologic 
based outcomes in clinical trials.  Likewise, inflammation-based interventions to improve 
outcomes using targeted and broad-based anti-inflammatory therapies do not improve outcomes 
in blunt trauma patients with HS 
25
.  Researchers have increasingly recognized how trauma-
associated inflammation is enacted by a highly orchestrated network of immunologic mediators 
5,26-30
  and failure of immunomodulation to improve outcomes after TBI or blunt trauma reflects 
how traditional interventions do not affect the marked complexities of the immune response 
13,26,28
.  Recently, blood purification by non-selective hemoadsorption (HA) has been introduced 
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as an inflammation modulating intervention
18,31-35
. In contrast to pharmaceutical interventions,
HA physically removes biologically active molecules from circulation and does not rely on 
interactions between an agent and cell surface receptors.   HA reduced circulating concentrations 
of immunoactive molecules in patients with sepsis syndrome 
32,33,36-38
 and when used in tandem
with extracorporeal circulation in cardiopulmonary bypass surgery 
31,35
 leading to improved
outcomes in both patient populations.  Little is known how HA reduces circulating 
concentrations of immunologic mediators and affects outcomes after trauma.  In this study, we 
hypothesized that HA would reduce circulating levels of immunologic mediators in rats 
subjected to TBI and HS leading to improved clinical outcomes.  The hypothesis was tested in 
rats, subjected to a combined injury including a controlled cortical impact (CCI) brain injury 
followed by HS.  Rats were treated with either therapeutic or sham HA interventions.  Our 
primary outcome was mortality by 96 hours after injury. 
Methods 
Experimental Protocol:  All procedures were approved by the Indiana University School of 
Medicine IACUC.  Two groups of Sprague Dawley male rats, 300 to 325 grams in weight, were 
tested.  All rats were allowed seven days of free cage activity to acclimate to their surroundings 
with ad lib water and diet prior to testing.  All rats were subjected to the same injury including 
TBI followed by HS.  The experimental group was treated with HA at the conclusion of injury 
and the sham treatment group had sham circulation after injury. Following resuscitation from 
HS, the extracorporeal circuit was immediately established with either HA or sham treatment.  
Experimental and sham treatments lasted for 180 minutes based on previous studies using HA in 
rats 
36,37
.  Following sham or experimental treatment, animals were returned to individual cages
and awakened from anesthesia.  They were allowed free cage activity and ad lib diet.  We 
analyzed 14 experimental and 19 sham rats in a 1:1 randomized design.  The increased numbers 
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of rats in the sham group resulted from greater numbers of death during sham treatment in an 
attempt to equalize numbers of rats surviving to 96 hours. 
Closed Cortical Impact Model: TBI was induced using a CCI model.  Rats were anesthetized via 
a nasal mask, and the rat's head was secured to a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA). A 7-mm craniotomy was made between the lambda and bregma and centered over 
the right fronto-parietal cortex lateral to the central suture with dura intact. The impact device 
(Benchmark Stereotaxic Impactor; Myneurolab) struck the right fronto-parietal cortex with a 
velocity of 4.0 m/s, tissue deformation of 2.5 mm, and impact duration of 100 ms with a 5-mm 
impactor tip.   
Hemorrhagic Shock Model: HS was established using a catheter inserted into the right femoral 
artery under loupe dissection. The artery was entered with a small intra-arterial catheter that was 
connected to a blood pressure transducer. A second catheter was surgically inserted using 
identical methods into the left femoral vein.  Blood was removed at 0.5 ml/minute from the 
arterial catheter until systolic blood pressure was reduced to 40 mmHg which was maintained for 
60 minutes by further controlled hemorrhage or saline infusion into the venous catheter as 
dictated by ongoing blood pressure measurements.  Subsequently, rats were resuscitated via 
autotransfusion of shed blood, augmented with normal saline if necessary, to restore the systolic 
blood pressure to > 90 mmHg.  
Hemoadsorption and Sham Treatment:  Following HS, the rats were subsequently connected to 
an extracorporeal circuit to administer HA or sham treatment.  The circuit included outflow from 
the right femoral artery catheter, passage through the treatment or sham cartridge, and return 
flow into the left femoral vein (Figure 1).  The volume of the entire circuit was approximately 
2.2 ml of blood representing less than 10% of the rats circulating volume.  In HA treatment 
animals, the circuit blood flowed through a 2.0 ml cartridge that contained proprietary beads 
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purpose designed to adsorb circulating molecules between 5.0 KDa and 60 KDa (Cytosorbents; 
Monmouth Junction, NJ).  In sham treatment animals, blood flowed through a 1.2 ml canister 
without beads that was reduced in size to equalize the volume of blood within the circuit in sham 
and experimental animals.  Following treatment, the tubing was removed and local hemostasis 
was obtained by direct pressure.  Surgical wounds were closed with silk suture.   
Blood Collection:  Approximately 0.5 ml of blood was aspirated from the venous catheter in 
K2EDTA-coated MiniCollect tube (Greiner Bio-One, Monroe, NC) immediately prior to injury 
(baseline), after injury but before the onset of sham or experimental treatment (0hr), at hourly 
intervals during experimental or sham treatment (1hr, 2hr, and 3hr), and at 24hr, 48hr, and 96hr 
after injury from the tail vein.   The plasma was isolated by centrifugation at 5,000 rpm for 10 
min and was frozen at -80°C until use.    We measured 27 biomolecules using a multiplex panel 
(RECYMAG65K27PMX, Millipore,  Billerica, MA) including interferon gamma (IFNγ), 
granulocyte colony stimulating factor (G-CSF), Eotaxin, Interleukin (IL)-2, IL-6, epidermal 
growth factor (EGF), Monocyte Chemotactic Protein-1 (MCP-1), interferon gamma induced 
protein 10 (IP-10), CXC motif ligand 1/keratinocyte derived cytokine/cytokine induced 
neutrophil chemoattractant (GRO/KC/CINC-1), granulocyte macrophage colony stimulating 
factor (GM-CSF), IL-1α, Leptin, IL-13, IL-10, IL-12p70, vascular endothelial growth factor 
(VEGF), Fractalkine, CXC motif ligand 5 (LIX), macrophage inflammatory protein 1 alpha 
(MIP-1α),  IL-4, IL-1β, IL-5, IL-17a, IL-18, MIP-2, Tumor Necrosis Factor Alpha (TNFα), and 
chemokine ligand 5 (Rantes).   
Histology:  Three rats from both the sham and HA treatment groups that survived the experiment 
along with three control rats that had no surgery were anesthetized, perfused with PBS and fixed 
with 4% paraformaldehyde in PBS.  After being post fixed overnight, five sets of coronal 
sections containing the hippocampus were cut (40 µm) with a vibratome (VT 1000; Leica, 
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Nussloch, Germany) and collected in PBS.  One set of sections was stained with standard 
hematoxylin and eosin (H&E).  The sections were mounted onto slides, air dried, dehydrated in 
graded series of ethanol, infiltrated in xylene, and embedded in paraffin.  The slides were then 
examined with a microscope (BX50; Olympus, Tokyo, Japan).  Images were acquired with a 
digital camera coupled to control software (DP70-BSW; Olympus) at 4X and 20 X 
magnification.   
Statistical analysis:  Death times were recorded for all rats that did not survive.  Survival 
functions were estimated using the product limit method and Kaplan-Meier curves were plotted. 
Time to death was compared between groups using the logrank test. 
     Two separate analyses were performed to evaluate biomarker concentrations.  We compared 
experimental and sham treatment rats to evaluate treatment effects on mediator concentrations 
during treatment and after treatment.  In addition, we compared survivor and non-survivor rats 
from the entire cohort of rats regardless of intervention to investigate biomarker changes that 
occurred after injury or any pre-injury differences in biomarkers that were associated with 
survival or death.  Only one non-survivor lived past the 24hr time point, so the changes in 
biomarkers between survivor and non-survivor rats were analyzed from baseline through 3hr 
post-injury.   
     In both analyses, a random effects mixed model was used to assess levels of biomarkers 
during the three hour treatment time period. Of primary interest was the interaction term between 
group and time, assessing the change in circulating biomarkers over time between 1) sham and 
experimental groups; and 2) survivor and non-survivor rats from the entire cohort..  Available 
biomarker levels post-treatment were considered as repeated outcome measures, while baseline 
level was included in the model as a covariate.  Since the sample sizes were modest, an 
unstructured covariance matrix was not used.  Constant correlation between measurements was 
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assumed and to minimize the number of parameters to be estimated, a compound symmetric 
covariance structure was used.   
     To determine if there were differences between the two comparison groups at individual time 
points during testing, we compared mean values at each time point between groups using t-tests.  
In addition, we compared mean values at individual time points during the treatment time period 
(1hr, 2hr, and 3hr) with the injury values (0hr) within each group using t-tests to determine 
longitudinal changes within each group during the treatment time frame.  Finally, to determine 
residual effects of treatment on changes in mediators, biomarker values at 24hr, 48hr, and 96hr 
were compared to baseline values in HA and sham treated rats using t-tests.   
Results 
Clinical Outcomes:  Survival improved from 47% (9 of 19 rats) in sham treated rats to 86% (12 
of 14; p = 0.04) in experimental rats.  Nine of the ten sham treated rats died within 24 hours of 
injury.  The two HA rats that died did so during HA treatment.  Figure 2 depicts survival curves 
for HA and sham treated rats. Histologic evaluation demonstrated no differences in control, sham 
treated (untreated) and HA (treated) rats (Figure 3). 
The Effect of HA on Circulating Concentrations of Biomarkers.   HA decreased IL-2 throughout 
the entire treatment period and also decreased Eotaxin, IL-1α, IL-6, IL-13, MCP-1, and TNFα at 
discreet time points during the treatment period compared to sham treated animals. 
(Supplemental Figure 1).  Seven of 27 biomarkers were elevated at one or more discreet time 
points during treatment (1hr to 3hr) compared to the immediate post-injury (0hr) values, and no 
biomarkers were decreased during treatment in sham treated rats.  In contrast, only three of 27 
biomarkers were elevated at one or more discreet time points during treatment compared to post-
injury values in HA rats, and IP-10, GM-CSF, Fractalkine and IL-18 were decreased at one or 
more discreet time points during treatment compared to post-injury values in HA rats 
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(Supplemental Figure 1).  Representative HA effects are selectively illustrated in temporal 
changes in GM-CSF, IL-6, IL-18, and TNFα (Figure 4).  HA reduced concentrations of GM-CSF 
(at 3hr) and IL-18 (at 1hr and 2hr) compared to immediate post-injury concentrations.  IL-6 (at 
1hr) and TNFα (at 3hr) demonstrated decreased concentrations in HA treated rats compared to 
sham treated rats.   
     Six biomarkers remained elevated above baseline values at 24hr to 96hr after injury in sham 
rats.  In contrast, during the same time period only two biomarkers were elevated above baseline 
values in HA rats (Supplemental Figure 1). MCP-1, IL-12p70, and IL-5 selectively illustrate 
differences in sham treatment and HA on changes in residual inflammation (Figure 5).  During 
the treatment window, differences in concentrations in MCP-1, IL-12p70, and IL-5 between HA 
and sham rats were minimal.  However at 24 and 48 hours after treatment, trends toward large 
increases in circulating concentrations of these molecules were measured in sham rats compared 
to HA rats (differences not statistically significant).  In summary, HA resulted in decreases in 
circulating concentrations in several biomarkers compared to sham treatment, but the majority of 
cytokines were not affected by HA treatment.    
Biomarker Concentrations in Survivor vs. Non-Survivor Rats:  We investigated differences in 
circulating concentrations of biomarkers between survivor and non-survivor rats regardless of 
intervention to identify candidate biomarkers that were associated with death or survival.  
Thirteen of 27 cytokines were significantly (p < 0.05) reduced in survivor rats over the entire 
three hour treatment period (IFNγ, EGF, VEGF, IP-10, GRO-KC-CINC1, Fractalkine, MIP-2, 
Rantes, Leptin, IL-2, IL-4, IL-6, IL-10, and IL-19) or increased (Leptin) compared to non-
survivor rats (Supplemental Figure 2).  Eotaxin, IL-1α, IL-4, IL-6, IL-17a, IL-18, MCP-1, GRO-
KC-CINC, VEGF, and Fractalkine were all significantly reduced at one or more discreet time 
points from 0hr to 3hr in survivors compared to non-survivors.  MIP-1α was significantly 
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elevated 3hr after injury in survivors compared to non-survivors.  There were trends of increased 
IL-17a (p = 0.090), increased IFNγ (p = 0.087), and decreased Leptin (p = 0.070) at baseline 
prior to injury in non-survivors compared to survivors.  Distinct biomarker patterns in survivors 
compared to non-survivors are selectively illustrated in Figure 6.  EGF and IL-10 diverged 
within the first hour after injury between the survivors and non-survivors.  In contrast, IFNγ was 
higher in non-survivors even prior to injury and demonstrated little change during the treatment 
time period.  Finally, IL-18 increased more in non-survivors compared to survivors immediately 
after the injury and prior to any treatment. In summary, temporal changes in biomarkers 
illustrate broad-based differences in circulating biomarker concentrations in surviving and non-
surviving rats. 
Discussion 
     Our data support the hypothesis that HA of circulating blood improves survival in rats 
subjected to TBI and HS.  HA improved survival from 47% to 86%.  HA reduced circulating 
concentrations of several cytokines, but it is likely that HA-mediated effects were caused by 
changing concentrations of molecules that were not quantified in this study.  Only IL-2 and 
Leptin were significantly different in HA rats compared to sham rats throughout the entire 
treatment period and Leptin concentrations were actually increased in HA rats.  In addition, HA 
resulted in reductions of only six of 27 biomarkers compared to sham treated rats at discreet time 
points during the treatment period.  While HA reduced mortality, causation between changes in 
circulating concentrations of any of the measured biomarkers and survival is unproven.  HA non-
selectively reduces circulating concentrations of molecules in the 5KDa to 60KDa range which 
would include an expansive array of other bioactive molecules that could have affected outcomes 
in this experiment. Regardless of its mechanism of action, non-selective HA was highly effective 
in improving survival in rats subjected to TBI with HS.  
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     It is unknown how HA would affect outcomes in rats subjected to isolated TBI or isolated HS.  
In preliminary model development work, our rats routinely survived the CCI injury or HS 
performed in isolation.  However, our survival rate was less than 50% when we combined the 
injuries during model development.  Therefore, we chose to use the combined TBI/HS injury and 
focus on how treatment affected mortality.  Histologic evaluation of the hippocampal region 
demonstrated no appreciable neuronal cell death in sham or treated rats indicating that the 
combined TBI/HS used in this model did not lead to neuronal cell death in unimpacted regions.  
It is possible that HA prevented neuronal death in brain tissue that was directly damaged by 
impact leading to improved survival.  Likewise, it is possible that HA might improve other 
neurologic-based outcomes.  However the effects of HA on injured brain tissue and on 
neurologic outcomes are unknown.  Finally, the mechanisms by which HA prevented death in 
rats subjected to TBI and HS are not known. 
      Trauma incites an immunologically mediated response that typically is self-regulating and 
concentrations of circulating immunologic mediators return to baseline values as the injury 
resolves 
39
.  However, in some patients, immunologic homeostatic mechanisms fail and patients 
develop sustained elevated levels of inflammation which are associated with trauma-adverse 
phenotypes including multiple organ failure and nosocomial infections 
5,28
.  Detailed mechanistic 
structures of inflammation and progression of the immunologic response to injury continue to 
develop but are far from understood. The marked complexities and coordination of inflammation 
after injury are emerging as computational analyses have uncovered time-dependent and spatial 
networks of immunologic orchestration 
5,26,27,40-42
.   Our data illustrated some intricacies of 
immunologic orchestration.  For example, several of the mediators such as G-CSF and MCP-1 
(Supplemental Figure 1) were minimally affected by injury or HA treatment, but were notably 
greater in sham rats 24hr to 48hr after injury.  Likewise other mediators such as VEGF, 
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Fractalkine, MIP-1α, and IL-13 were all decreased by HA during treatment but 24hr later were 
unchanged compared to sham controls.  These observations align with contemporary models of 
the immunologic response to injury which increasingly describe a complex molecular 
orchestration of pro-inflammatory and anti-inflammatory signals 
26,27,41
. Computational 
analyses are necessary to decipher how interventions such as HA affect immunologic 
orchestration and affect outcomes after injury.  
     The data from this experiment suggest that immunologic response differences between 
specimens likely affect outcomes.  For example, there were trends toward higher IFNγ, higher 
IL-17a and lower Leptin in non-survivors at baseline prior to any injury (Supplemental Figure 2).  
Likewise, there were trends toward greater injury-associated increases in IL-18 and Fractalkine 
in non-survivors compared to survivors at 0hr prior to any intervention. Finally, nearly half of 
the biomarkers were different during the initial three hour time period after injury in survivors 
compared to non-survivors (Supplemental Figure 2).  Further investigation will be necessary to 
understand how individual differences in immune response affect outcomes. 
     Inflammation mitigation to improve outcomes after TBI has been tested extensively in animal 
models.  Bergold thoroughly summarized results from 95 distinct animal trials of a variety of 
anti-inflammatory interventions to improve outcomes after TBI 
17
.  Collectively, these results
unambiguously demonstrate that inflammation exacerbates TBI and that inflammation mitigation 
can reduce secondary brain injury.  In addition, reducing secondary brain injury consistently 
improved histologic and phenotypic outcomes in specimens with inflammation blockade.  
However, none of these studies quantified treatment effects on mortality.  In addition, while 
animal evidence has demonstrated consistent improvements in a variety of molecular, histologic, 
motor, and cognitive outcomes, similar inflammation-mitigation interventions in human trials 
have uniformly failed to improve outcomes after TBI 
18-24,43
.  These trials have included broad-
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based corticosteroid interventions 
18-20,24
 and targeted interventions that block potent cytokines 
including TNFα and IL-1 23,43.  Consensus amongst authorities is that immunologic-based 
interventions have failed to affect the broader complexities of temporal and spatial orchestration 
of the immune response to injury leading to clinical failure 
13
.   
     HA has a unique mechanism of action that physically removes molecules from circulation.  It 
is effective at removing cytokines as many of these molecules are within the 5 KDa to 60 KDa 
purification envelope of Cytosorbents.  In contrast to traditional pharmaceuticals, HA does not 
mediate its effects by interacting with biologically active cell surface receptors.  It is possible 
that traditional pharmaceutical mechanisms (cell surface receptor blockade, cell surface receptor 
stimulation, nuclear transcription effects) may be altered by injury and that a simplified approach 
that does not rely on any interaction with cells offers an effective immunomodulation strategy.  
HA has been shown to improve outcomes in a variety of animal models and in clinical 
applications.  Zhang and colleagues used HA in rats subjected to sepsis through cecal puncture 
38
.  In this model, the investigators demonstrated modest reductions in several cytokines 
including decreases in IL6 similar to what we measured in this experiment. The investigators 
demonstrated modest improvements in mortality from 50% in untreated animals to 26% in 
treated animals.  These data parallel previous small animal experimentation by the same research 
group that HA reduces multiple mediators during treatment and on a delayed basis 
36,37,44
.  
Clinically, in 27 patients who developed septic shock with kidney failure, HA improved 
hemodynamic parameters, reduced blood lactate levels, and reduced predicted mortality rates.  
Effects were most pronounced in patients treated within 24 hours of developing kidney failure 
33
.  
Trager and colleagues reported reductions in cytokines and improved outcomes in a retrospective 
series of 16 patients who developed SIRS after cardiopulmonary bypass 
35
.   Recently in a 
randomized controlled clinical trial, it was shown that HA during surgery reduced circulating 
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levels of IL-10 in patients placed on cardiac bypass 
31
.  However, changes in circulating IL-10
did not extrapolate into any clinical improvement.  Likewise in several other clinical trials, the 
effect of HA on phenotypic improvement are encouraging but not proven 
18,32,34,45
.
     There are multiple potential sources of error in our experiment.  The entire experimental setup 
is technically demanding and achieving uniform surgical access to homogenize the brain injury, 
produce consistent HS, normalize resuscitation, and produce consistent HA was challenging.  
Fortunately, we had performed these procedures for several other protocols and had become 
proficient with our surgical methods prior to embarking on this protocol.  The cause of death in 
rats was unknown in this experiment.  The high mortality rate can be safely assumed to result 
from the combined injury as we observed minimal mortality in rats subjected to either isolated 
CCI or HS in model development.  In addition, surviving rats in both sham and treatment groups 
resumed presumably normal motor and feeding behavior consistent with other protocols using 
similar or identical CCI parameters inducing brain injury 
17
.  This suggests the magnitude of the
TBI was moderate, but the TBI magnitude was not formally quantified in this experiment.  It is 
unknown how HA prevented death in our model and HA reductions in mortality may have been 
independent from preventing propagation of TBI.  For example, it is possible that HA prevented 
death by reducing the combined effects of TBI and HS on cardiovascular function.  We only 
quantified changes in mortality and we did not quantify motor-based or functional outcomes in 
rats that survived.  Therefore, we do not know what the effects of HA are on longer-term 
neurological outcomes after TBI.  We measured an expanded panel of cytokines felt to reflect a 
trauma-relevant menu of immunologic mediators.  However, HA non-selectively adsorbs 
molecules in the 5 KDa to 60 KDa size range and it is distinctly possible that improvements in 
survival were affected by changes in other molecules that we did not quantify.  Additionally, it 
was anticipated that HA would result in broad reductions in circulating immunologically active 
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molecules and it is not surprising that there were general increases in several of the mediators in 
non-surviving rats compared to survivors.  While the molecules we measured have been 
integrated into a multiplex panel relevant to trauma and shock, it is unknown how changes in any 
individual molecule affected survival.  However, the data do provide some foundation and 
direction for more in-depth mechanistic studies pertaining to immunologically mediated 
outcomes after injury. 
     In conclusion, blood purification by HA reduced circulating concentrations of multiple 
cytokines in rats subjected to combined TBI and HS.  HA increased survival from 47% in sham 
treated rats to 86 % in experimentally treated rats.  HA physically removes biologically active 
molecules from circulation which is distinct from pharmaceutical inflammation-mitigation 
interventions that block cell surface receptors, modulate transcription and modulate translation.  
HA has been safe and effective in human trials and offers a new alternative to be investigated to 
improve outcomes in patients with TBI and HS.  
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Figure Legends 
Figure 1.  Experimental setup for sham treatment and hemoadsorption (HA).  The femoral artery 
catheter (FA) is in series with the cartridge (CYT).  In HA treated rats, a 2.0 ml cartridge 
contained proprietary beads (Cytosorbents; Monmouth Junction, NJ) that removed circulating 
molecules in the 5 KDa to 60 KDa range.  In sham rats, the cartridge was empty and reduced to 
1.2 ml to equalize the volume of blood in the circuit in both groups.  Outflow rate from the 
cartridge was maintained with a pump and returned to the femoral vein catheter (FV). 
Figure 2.  Survival curves for experimental rats treated with HA compared to sham treated rats 
demonstrates efficacy of HA treatment to prevent death.  Two of 14 HA rats died and did so 
early after injury during HA treatment.  Ten of 19 sham treated rats died with only one rat 
surviving beyond 24hr after injury.   
Figure 3.  Representative Hematoxylin and Eosin stained hippocampal sections from uninjured 
rats (Control), sham-treated (Untreated), and HA-treated (Treated) demonstrated no fundamental 
differences in cell death or inflammatory composition in the sham-treated compared to HA-
treated rats.  Higher magnification shows similar cell viability and inflammatory changes in the 
Cornu Ammonis (CA)1, CA3, and Dentate Gyrus regions.  
Figure 4.  Four purposefully selected biomarkers demonstrating how HA (dashed lines) affected 
circulating concentrations of immunoactive molecules compared to sham rats (solid line).   An 
single asterisk (*) denotes statistically significant difference in biomarker concentration (p < 
0.05) in HA treated rats compared to sham treated rats at that specific time point;  ** denotes 
significantly different biomarker concentration (p < 0.05) at that specific time point compared to 
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the 0hr value in HA treated rats; ## denotes significantly different biomarker concentration (p < 
0.05) at that specific time point compared to 0hr value in sham treated rats.  HA reduced GM-
CSF and IL-18 (**) during the treatment time period compared to immediate post-injury values 
at 0hr.  In contrast, in sham treated rats, GM-CSF, IL-6, and TNF-α were significantly increased 
in concentration during the treatment period (##) compared to immediate post-injury values at 
0hr.  Concentrations of GM-CSF at 96hr, IL-6 at 1hr and TNF-α at 3hr were lower in HA treated 
rats compared to sham treated rats (*).   Finally, the injury caused a significant increase in IL-18 
in both sham treated rats (##) and HA treated rats (**) at 0hr compared to baseline values.   
 
Figure 5.  Changes in biomarker concentrations in MCP-1, IL-5, and IL-12p70 selectively 
illustrate three mediators that had relatively minimal change in concentration after injury or 
during treatment but had different trajectories during the subsequent 24hr to 96hr after injury in 
HA treated rats (dashed lines) compared to sham treated rats (solid lines).  These three mediators 
demonstrated trends toward greater increases during the 24hr to 96hr time frame in sham treated 
rats compared to HA treated rats.  MCP-1 concentrations were greater at 24hr, 48hr, and 96hr in 
sham (###) and HA (***) treated rats compared to baseline values with trends toward greater 
increases in sham treated rats.  Likewise, IL-5 was increased over baseline values at 48hr and 
96hr after injury in sham treated rats (###) with a trend (p = 0.088) toward being greater than HA 
treated rats at 48hr after injury.  Finally, IL-12p70 trended higher in sham treated rats at 24hr (p 
= 0.091 ) and 48hr (p = 0.104) compared to HA treated rats.  
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Figure 6.  Selected data demonstrate that there were distinctive biomarker patterns that occurred 
immediately after injury (0hr) and during the treatment time period (0hr – 3hr) in survivors 
(dashed lines) compared to non-survivors (solid lines) drawn from the entire cohort of rats 
regardless of treatment.  EGF, IL-18, IL-10, and IFNγ illustrate four mediators that were 
significantly increased in non-survivors compared to survivors over the entire treatment period 
(horizontal bar with associated p value above data points).  Distinctive patterns are illustrated 
within these four biomarkers. EGF and IL-10 had similar baseline and post-injury (0hr) values in 
survivors and non-survivors, but diverged in magnitude after the injury and during the three hour 
treatment time frame.  In contrast, IL-18 diverged between survivors and non-survivors after the 
injury.  Finally, IFNγ was seemingly different between survivors and non-survivors at baseline, 
immediately after injury and during the treatment time frame. 
Supplemental Figure 1.  Time-dependent changes in all 27 biomarkers in HA treated rats (n = 14; 
dashed lines) and sham treated rats (n = 19; solid lines).  A single asterisk (*) denotes a 
significant difference (p < 0.05) between sham rats and HA rats at an individual time point (i.e. 
IL-1α at the 1hr time point).  In HA treated rats, ** denotes a statistically significant decrease or 
increase in biomarker concentration (p < 0.05) at the denoted time point compared to the 
biomarker concentration in the HA group at the immediate post-injury 0hr time point.  Likewise, 
in sham treated rats, ## denotes a statistically significant decrease or increase in biomarker 
concentration (p < 0.05) at the denoted time point compared to the biomarker concentration in 
the sham group at the post-injury 0hr time point.   A triplicate symbol of *** in HA rats or ### in 
sham rats denotes a statistically significant increase or decrease in a biomarker concentration (p 
< 0.05) at the 24hr, 48hr, or 96hr time point compared to baseline values of the biomarker within 
each group.  These comparisons were conducted to identify residual changes in biomarker 
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concentrations in sham or treatment groups.  Finally in Leptin and IL-2, the horizontal bar above 
the data points and associated p-value denotes statistically significant differences in biomarker 
concentration between sham and HA rats over the entire treatment period (0hr to 3hr).  There 
was a trend toward a difference over the treatment time period in GM-CSF (p = 0.068) and IP-10 
(p = 0.068). 
 
Supplemental Figure 2.  Time-dependent changes in all 27 biomarkers comparing rats that either 
survived to 96hr (n = 21; dashed lines) or died prior to the 96hr time point (n = 12; solid lines) 
from the entire cohort of rats regardless of intervention.  Note of the 12 rats that died, 11 died 
prior to the 24hr time point so biomarkers in this figure are presented only until the 3hr time 
point.   Biomarkers denoted by a single asterisk (*) are significantly different in concentration (p 
< 0.05) between survivors and non-survivors at that time point.  Biomarkers denoted by either ## 
(non-survivors) or ** (survivors) are  significantly different (p < 0.05) compared to the 0hr value 
within the same group at the denoted time point (i.e. IL-4 is significantly higher in non-survivors 
at 1hr and 3hr compared to the 0hr value in non-survivors).  A horizontal bar either above or 
below the 0hr to 3hr data with an associated p value denotes that biomarker concentrations were 
significantly different (p < 0.05) over the entire treatment time period in non-survivors compared 
to survivors.  Fourteen of the 27 biomarkers were significantly different over the entire treatment 
period in survivors compared to non-survivors.   
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